Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Key Stats

• Today's Range: $4.00 to $5.46
• 50-Day Range: $3.31 to $5.30
• 52-Week Range: $3.03 to $14.80
• Volume: 57,263 shs
• Average Volume: 135,944 shs
• Market Capitalization: $4.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Titan Pharmaceuticals Stock Analysis - MarketRank™

Titan Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Titan Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Titan Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Titan Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Titan Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Titan Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Titan Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.11% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently decreased by 5.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Titan Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for TTNP on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.93% of the stock of Titan Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.49% of the stock of Titan Pharmaceuticals is held by institutions.

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed this year?

Titan Pharmaceuticals' stock was trading at $3.26 at the start of the year. Since then, TTNP shares have increased by 62.6% and is now trading at $5.30.
View the best growth stocks for 2025 here.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings data on Thursday, March, 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals's stock reverse split on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TTNP
• CIK: 910267
• Web: www.titanpharm.com
• Phone: (650) 244-4990
• Fax: 650-244-4956
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): ($5.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,570,000.00
• Net Margins: N/A
• Pretax Margin: -182,032.52%
• Return on Equity: -118.01%
• Return on Assets: -103.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.71
• Quick Ratio: 9.71

Sales & Book Value

• Annual Sales: $180,000.00
• Price / Sales: 26.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.82 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 914,000
• Free Float: 686,000
• Market Cap: $4.84 million
• Optionable: Optionable
• Beta: 1.25